A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry

被引:73
作者
Tang, Huaidong [1 ]
Mayersohn, Michael [1 ]
机构
[1] Univ Arizona, Coll Pharm, Dept Pharmaceut Sci, Tucson, AZ 85721 USA
关键词
allometric scaling; vertical allometry; clearance; protein binding; C logP;
D O I
10.1002/jps.20481
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Allometrically scaled data sets (138 compounds) used for predicting human clearance were obtained from the literature. Our analyses of these data have led to four observations. (1) The current data do not provide strong evidence that systemic clearance (CLs; n = 102) is more predictable than apparent oral clearance (CLpo; n = 24), but caution needs to be applied because of potential CLpo prediction error caused by differences in bioavailability across species. (2) CL, of proteins (n = 10) can be more accurately predicted than that of non-protein chemicals (n = 102). (3) CL, is more predictable for compounds eliminated by renal or biliary excretion (n = 33) than by metabolism (n = 57). (4) CL predictability for hepatically eliminated compounds followed the order: high CL (n = 11) > intermediate CL (n = 17) > low CL (n = 29). All examples of large vertical allometry (% error of prediction greater than 1000%) occurred only when predicting human CLs of drugs having very low CLs. A qualitative analysis revealed the application of two potential rules for predicting the occurrence of large vertical allometry: (1) ratio of unbound fraction of drug in plasma (f(u)) between rats and humans greater than 5; (2) C logP greater than 2. Metabolic elimination could also serve as an additional indicator for expecting large vertical allometry. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:1783 / 1799
页数:17
相关论文
共 162 条
[1]  
ADAMS WJ, 1989, CANCER RES, V49, P6328
[2]  
ADUSUMALLI VE, 1991, DRUG METAB DISPOS, V19, P1116
[3]   INVESTIGATION OF THE PHARMACOKINETICS OF ETHYNYLESTRADIOL IN WOMEN USING RADIOIMMUNOASSAY [J].
BACK, DJ ;
BRECKENRIDGE, AM ;
CRAWFORD, FE ;
MACIVER, M ;
ORME, MLE ;
ROWE, PH ;
WATTS, MJ .
CONTRACEPTION, 1979, 20 (03) :263-273
[4]  
BAGGOT JD, 1994, AM J VET RES, V55, P689
[5]   ABSORPTION, DISPOSITION AND PRELIMINARY METABOLIC PATHWAY OF C-14 RIFABUTIN IN ANIMALS AND MAN [J].
BATTAGLIA, R ;
PIANEZZOLA, E ;
SALGAROLLO, G ;
ZINI, G ;
BENEDETTI, MS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (06) :813-822
[6]   CLINICAL PHARMACOKINETICS OF ANTIEPILEPTIC DRUGS IN PEDIATRIC-PATIENTS .1. PHENOBARBITAL, PRIMIDONE, VALPROIC ACID, ETHOSUXIMIDE AND MESUXIMIDE [J].
BATTINO, D ;
ESTIENNE, M ;
AVANZINI, G .
CLINICAL PHARMACOKINETICS, 1995, 29 (04) :257-286
[7]   SERUM BINDING OF QUINIDINE IN EXPERIMENTAL ACUTE RENAL-FAILURE [J].
BELPAIRE, F ;
BOGAERT, M ;
DEBROE, M ;
MUSSCHE, M .
PHARMACOLOGY, 1977, 15 (04) :311-317
[8]   INFLUENCE OF ACUTE RENAL-FAILURE ON PROTEIN-BINDING OF DRUGS IN ANIMALS AND IN MAN [J].
BELPAIRE, FM ;
BOGAERT, MG ;
MUSSCHE, MM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 11 (01) :27-32
[9]   Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species:: Application to prediction of clearance in man [J].
Björkman, S ;
Redke, F .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2000, 52 (09) :1065-1074
[10]  
BOMBARDT PA, 1994, J PHARMACOL EXP THER, V269, P145